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C34, a Membrane Fusion Inhibitor, Blocks
HIV Infection of Langerhans Cells and
Viral Transmission to T Cells
Makoto Sugaya1, Oliver Hartley2, Michael J. Root3 and Andrew Blauvelt1
Development of topical microbicides that prevent sexual transmission of HIV is an active area of investigation.
The purpose of this study was to test the ability of the potent membrane fusion inhibitor C34, an HIV gp41
antagonist, to block HIV infection of human Langerhans cells (LCs) in an epithelial environment that mimics a
major route of HIV infection. We incubated freshly isolated epidermal explants containing LCs with various
doses of C34 before, during, and after exposing explants to HIV. Although C34 only partially blocked HIV
infection of LCs when pre-incubated with skin, it displayed full, dose-dependent inhibition when present
during and after viral exposure. The poor protection from HIV infectivity in pre-incubated samples is consistent
with mechanism of C34 inhibition and starkly contrasts to the full protection provided by PSC-RANTES, an entry
inhibitor that prevents HIV gp120 interaction with its co-receptor CCR5. Real-time PCR confirmed that C34
blocked HIV infection of LCs before reverse transcription and inhibited LC-mediated transfer of virus to T cells.
We conclude that C34, if used topically at susceptible mucosal sites, and if continually present, has the potential
to block sexual transmission of HIV.
Journal of Investigative Dermatology (2007) 127, 1436–1443. doi:10.1038/sj.jid.5700736; published online 25 January 2007
INTRODUCTION
HIV replication is a multi-step process that includes viral
attachment to cell-surface receptors and co-receptors, fusion
between virion envelope and cell membrane, reverse
transcription, DNA integration, viral protein synthesis, and
protease cleavage. Given the difficulty in developing an
effective vaccine against HIV, researchers have expanded
their focus on generating topical microbicides that could
block sexual transmission of HIV at mucosal sites (Lederman
et al., 2006). Topical microbicides that are virucidal or that
inhibit early steps in the HIV life cycle, such as viral
attachment, fusion, and cell entry, are preferable to drugs that
block late steps in the HIV life cycle, as they would
block initial viral integration into chromosomal DNA. In this
regard, we have previously shown that intravaginal topical
use of Na- (n-nonanoy1)-des-Scr1-[L-thioproline2, L-a-cyclo-
hexyl-glycine3] RANTES (PSC-RANTES) (regulated on activa-
tion normal T-cell expressed and secreted), an analogue of
RANTES that binds the HIV co-receptor CCR5 and disrupts its
interaction with the viral envelope glycoprotein Env, can
completely block intravaginal infection of simian immuno-
deficiency virus in rhesus macaques (Lederman et al.,
2004). As the cost to produce PSC-RANTES is likely to be
considerable, we have pursued additional drugs that block
early steps of the HIV life cycle and that could serve as
potential topical microbicides either alone or in combination
with PSC-RANTES.
HIV gp41, the transmembrane subunit of Env, has recently
emerged as a viable target for entry inhibition (Root and
Steger, 2004). Following the interaction of Env with cellular
receptors, gp41 undergoes a series of coordinated structural
changes, ultimately extending to insert its N-terminal fusion
peptide into target cell membranes (Pierson and Doms,
2003). Subsequently, the N- and C-terminal regions of the
gp41 ectodomain associate to form a trimer-of-hairpins that
juxtaposes the viral and cellular membranes in a manner
required for efficient fusion (Chan et al., 1997; Weissenhorn
et al., 1997; Melikyan et al., 2000; Markosyan et al., 2003).
Synthetic peptides derived from the C-terminal region of
the gp41 ectodomain block trimer-of-hairpins formation,
potently inhibiting viral entry (Jiang et al., 1993; Wild et al.,
1994; Lu et al., 1995). Denoted C-peptides, they bind
the N-terminal region of the gp41 ectodomain exposed
transiently in the extended intermediate conformation (Chan
et al., 1998; Furuta et al., 1998; Munoz-Barroso et al., 1998;
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Rimsky et al., 1998). One C-peptide, T-20, demonstrates
anti-viral activity in humans and has recently gained Food
and Drug Administration approval for use to treat acquired
immunodeficiency syndrome (Lalezari et al., 2003; Lazzarin
et al., 2003).
To test C-peptides as potential topical microbicides, we
have developed and utilized an ex vivo skin explant model
system (Kawamura et al., 2000, 2003, 2004; Ball et al., 2003;
Sugaya et al., 2004). This model utilizes suction blister roofs
(i.e., epidermal sheets) to analyze the mechanism by which
Langerhans cells (LCs) support initial HIV infection (Piguet
and Blauvelt, 2002). Although direct evidence of a dominant
role for LCs in HIV transmission between humans is difficult
to obtain, intraepithelial LCs have been shown to be the
major cell type infected following non-traumatic intravaginal
exposure to SIV in rhesus monkeys (Hu et al., 2000). We have
recently shown that pre-incubation of skin explants to drugs
that disrupt HIV Env attachment to its receptors specifically
blocks both the infection of LCs and their ability to transmit
virions to T cells (Kawamura et al., 2003, 2004). Fusion
inhibitors like C-peptides also represent attractive candidate
topical microbicides for the following reasons: (1) they inhibit
an early stage in the HIV life cycle; (2) they are likely to work
locally within tissue at nanomolar concentrations; and (3)
they target a gp41 sequence that is highly conserved,
decreasing the likelihood of rapid emergence of resistant
virus (Root and Steger, 2004). Here, using our skin explant
system, we show that the potent C-peptide C34 can block
both HIV infection of human LCs and LC-mediated transfer of
virus to T cells, providing impetus for future studies that
utilize C-peptides to block mucosal transmission of HIV.
RESULTS
Continuous presence of C34 dose dependently blocks HIV
infection of human epidermal LCs
Following established procedures to assess anti-viral efficacy
in the skin explant model (Kawamura et al., 2000, 2003,
2004; Ball et al., 2003; Sugaya et al., 2004), we first pre-
incubated blister roofs with different doses of C34 for
20 minutes and then added HIV for 2 hours. Skin explants
were then washed free of both virus and drug and cultured for
3 days, enabling epidermal LCs to migrate into the culture
wells. Productive HIV infection of LCs was assessed by flow
cytometry gated on cells intracellularly stained for HIV p24.
We previously showed that treatment with zidovudine (AZT),
which should have no effect on capture or surface binding of
HIV virions by LCs, diminished HIV p24þ LCs in a dose-
dependent manner (Kawamura et al., 2003). In addition, the
number of HIV p24þ LCs progressively increased over the
first several days after HIV exposure, indicating ongoing
active HIV replication within LCs (Kawamura et al., 2003).
Therefore, we concluded that all HIV p24þ LCs in this study
represented productively infected cells, rather than HIV that
was captured or bound.
C34 only partially blocked productive HIV infection of
LCs, even at micromolar concentrations (100- to 1,000-fold
greater than the IC50 (50% of the maximum possible
inhibitory response) for viral infection measured in vitro
(Chan et al., 1998) (Figure 1a and b). Likewise, C34 showed
only partial activity when added during the 3-day culture
period following the initial 2-hour exposure of the blister roof
to HIV (Figure 1c and d). In analogous virion washout
experiments using cultured CEM or HeLa cells, a similar
inability of C-peptides to block all HIV infection has been
observed (M.J. Root, unpublished results).
The results are consistent with the mechanism of
C-peptide inhibition; as they target an intermediate state in
the fusion process, C-peptides must be present at the time of
HIV membrane fusion. The absence of C34 during the initial
blister roof incubation enabled the HIV present during this
time to infect without hindrance. Similarly, the absence of
C34 during the 3-day incubation period permitted LCs to be
infected by virions that were not washed away, perhaps
because they were attached to the cellular glycocalyx (e.g.,
through lectin–glycan interactions) and had not yet interacted
with CD4 and a chemokine receptor. Consistent with these
postulates, C34 completely blocked LC infection in a dose-
dependent manner when present before, during, and after
exposing LCs to HIV (Figure 1e and f). The numbers of LC
migrating into the media during the 3-day culture period
were not affected by C34, suggesting that C34 was not toxic
to LCs at the dose range studied (1–1,000 nM).
Comparing the anti-HIV effects of C34, PSC-RANTES, and AZT
In order to compare blocking effects of drugs with different
modes of action, we performed experiments using 1 mM C34,
100 nM of PSC-RANTES (a RANTES analogue that inhibits
binding of HIV with its cellular co-receptor CCR5), and
100mM of AZT (a reverse transcriptase inhibitor). Skin
explants were incubated with one of these three drugs before
and during exposure to virus (labeled ‘‘pre/during’’), follow-
ing virus exposure during the 3-day culture period (labeled
‘‘post’’), or before, during, and after infection (labeled ‘‘all’’).
As we have previously reported (Kawamura et al., 2003,
2004), pre-incubation of LCs with PSC-RANTES completely
blocked LC infection (Figure 2). Protection from infection
after pre-incubation with PSC-RANTES would be expected
given its inhibitory mechanism, which involves rapid
induction of prolonged intracellular sequestration of CCR5
(Pastore et al., 2003; Hartley et al., 2004). Here, however,
PSC-RANTES partially blocked HIV infection (up to 50%),
even when LCs were exposed to drug following a 2-hour
exposure to virus (i.e., during the ‘‘post’’ period) (Figure 2). As
the inhibitory effects of PSC-RANTES are presumably limited
to the blocking of gp120 binding to CCR5, the observed
partial inhibition suggests that HIV Env/CCR5 interaction for
at least some of the infecting virions occurs during the 3-day
culture period following viral washout. Newly formed virus
emerging from initially infected LCs is probably the main viral
source in this type of experiment. To support this claim, we
previously showed that cells emigrating from HIV-exposed
explant tissue demonstrate classic ultrastructural features of
LC (e.g., Birbeck granules) and show clear evidence of virions
budding from cell surfaces (Kawamura et al., 2003). We also
previously ruled out the possibility that captured virus was a
source of infection following initial exposure, showing that
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Figure 1. Continuous presence of C34 dose dependently blocks HIV infection of human epidermal LCs. (a) Epidermal sheets were pre-incubated with different
doses of C34 for 20 minutes at 371C, exposed to HIV for 2 hours, washed three times to remove virus and drug, and cultured for 3 days. (c) Epidermal sheets were
exposed to HIV for 2 hours, washed three times to remove virus, and cultured for 3 days with different doses of C34. (e) Epidermal sheets were pre-incubated
with different doses of C34 for 20 minutes at 371C, exposed to HIV for 2 hours, washed three times to remove virus and drug, and cultured for 3 days with
different doses of C34. (a, c, e) In all experiments, ‘‘crawl-out’’ LCs were collected on day 3, stained with anti-HIV p24 and anti-MHC class II mAbs, and
examined by flow cytometry. (a, c, e) Representative dot plots are shown. (b, d, f) Summary of the percent HIV infection of LCs when compared to LCs incubated
with no drug in three separate experiments.
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treatment of crawl-out LCs with trypsin did not change p24
production in co-cultures containing LCs and T cells
(Kawamura et al., 2000). In addition, mannan, a C-type
lectin inhibitor that would be expected to interfere with
capture of HIV virions, showed no blocking effect in our
system (Kawamura et al., 2003 and data not shown).
Pre-incubation of skin explants with AZT partially blocked
HIV infection, whereas AZT completely blocked HIV
infection of LCs when present during the 3-day culture
period (Figure 2). Taken together, these results are consistent
with the known mechanisms of action of each of these three
drugs, with PSC-RANTES acting on the earliest step (Env-
receptor interaction) in the HIV life cycle, C34 acting on a
slightly later step (receptor-induced membrane fusion), and
AZT acting on the latest step (inhibition of reverse trans-
criptase following viral RNA entry into the cytoplasm).
Moreover, the ‘‘post’’ PSC-RANTES results and the ‘‘pre/
during’’ and ‘‘post’’ C34 results also reveal that about half of
all HIV-infected LCs in our model system are infected during
the 2-hour exposure to virus, and about half are infected
during the subsequent 3-day culture period.
Comparing the ability of C34, PSC-RANTES, and AZT to block
HIV DNA integration into LC chromosomal DNA
In experiments shown in Figures 1 and 2, we utilized anti-
HIV p24 intracellular staining and flow cytometry to detect
and quantify productive infection of LCs 3 days following
exposure to HIV. Unlike protease inhibitors that block
maturation of HIV particles into infectious virions, all three
tested drugs block steps in the HIV life cycle before
integration of viral cDNA into the host cell genome. In order
to confirm that C34 does indeed block before viral cDNA
integration, we measured HIV gag DNA (which should only
be present following reverse transcription) in LCs via real-
time PCR. Consistent with the flow cytometry results, C34 in
the ‘‘all’’ incubation condition period completely blocked
HIV gag DNA expression, whereas C34 in the ‘‘pre/during’’
or ‘‘post’’ incubation conditions only partially blocked HIV
gag DNA expression (Figure 3a and b). Consistent with their
mechanisms of action, PSC-RANTES in the ‘‘pre/during’’
incubation condition and AZT in the ‘‘all’’ incubation
condition completely blocked viral DNA integration into
LCs (Figure 3a and b). This second, more sensitive measure of
HIV infection confirms that all three anti-viral drugs, with
different modes of action, can successfully block HIV
infection of LCs present within skin explants.
C34 blocks the ability of LCs to transmit HIV to
co-cultured T cells
The intended consequence of blocking HIV infection of LCs
in genital mucosa is to disrupt LC-mediated viral transmission
to T cells, which likely occurs in submucosal epithelium and
in draining lymph nodes. We previously showed that when
HIV attachment to LCs was blocked by PSC-RANTES, viral
transfer to T cells was also blocked (Kawamura et al., 2003,
2004). We examined whether C34 and AZT, drugs with
different modes of action when compared to PSC-RANTES,
could also block LC-mediated viral transmission to T cells.
T cells co-cultured with LC that had been treated with C34
(‘‘all’’ incubation), PSC-RANTES (‘‘pre/during’’ incubation),
or AZT (‘‘all’’ incubation) expressed almost no intracellular
HIV p24 protein (Figure 4). Culture supernatants from these
experimental conditions were also negative for HIV p24
protein (Table 1), implying that the treated LCs failed to
transmit HIV to T cells. These results suggest that blocking
HIV infection of LCs either at a viral attachment step, a viral
fusion/entry step, or at a reverse transcription step is sufficient
to prevent viral transfer to T cells in our model system.
Although it is possible that small amounts of residual drug
had anti-HIV effects in T cells in later days of our assays, the
bulk of our findings support the idea that C-type lectin-
mediated capture of HIV is not a major pathway by which
epidermal LCs transfer virus to T cells (Kawamura et al.,
2003, 2004).
DISCUSSION
The HIV pandemic has continued unabated for over 25 years
with the vast majority of new infections occurring across
genital mucosal tissue (Royce et al., 1997; UNAIDS, 2006). In
the absence of a prophylactic vaccine against HIV, health
measures designed to limit the numbers of new cases of
sexually transmitted HIV infection have included the use of
topical microbicides, drugs, or compounds that can be
applied to genital tissue before sexual intercourse and
potentially block transmission of HIV (Lederman et al.,
2006). Most compounds that have been put forth as potential
microbicides, including nonoxynol-9 (Van Damme et al.,
2002), BufferGel (Patton et al., 2004), cyanovirin (Tsai et al.,
2004), C31G (Mauck et al., 2004), and cellulose acetate
phthalate (Neurath et al., 2002), work in a nonspecific
virucidal manner when tested in the laboratory. Limitations
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Figure 2. Comparing the anti-HIV effects of C34, PSC-RANTES, and AZT.
Summary of three independent experiments showing anti-HIV effects of C34
(1 mM), PSC-RANTES (100 nM), or AZT (100 mM) when compared to LCs
incubated with no drug. Skin explants containing LCs were incubated
with drugs in three different conditions: ‘‘pre/during,’’ ‘‘post’’, and ‘‘all’’
(as defined in the Methods and Methods). In all experiments, ‘‘crawl-out’’
LCs were collected on day 3, stained with anti-HIV p24 and anti-MHC
class II mAbs, and examined by flow cytometry.
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that hinder the clinical usefulness of these compounds
include their potential toxicity to mucosal epithelial cells
following sustained use (Van Damme et al., 2002; Dezzutti
et al., 2004). Alternatively, we and others have focused on
candidate topical microbicides that target specific steps in the
HIV infection life cycle. Our previous work with PSC-
RANTES, a CCR5 inhibitor that blocks viral attachment to cell
membranes, has shown the validity of such a targeted
approach for candidate microbicides (Lederman et al.,
2004). In this study, we show that inhibitors of gp41-
mediated viral membrane fusion might also be of potential
use in the development of topical microbicides.
C34, an HIV fusion inhibitor that disrupts the function of
HIV gp41 in a manner similar to T-20 (enfuvirtide), inhibited
HIV infection of epidermal LCs in a dose-dependent manner
when skin explants exposed to HIV were continuously
incubated with drug. At the highest dose tested (1mM), C34
completely blocked LCs infection (Figure 1), and we showed
that the block occurred before reverse transcription of HIV
(Figure 3), as expected based upon the anti-viral mechanisms
of these two drugs (Jiang et al., 1993; Chan et al., 1998;
Malashkevich et al., 1998; Munoz-Barroso et al., 1999). In
addition, we showed that C34 also blocked the ability of HIV-
exposed LCs to transfer virus to co-cultured T cells (Figure 4
and Table 1). Interestingly, C34 was shown to block mucosal
simian immunodeficiency virus infection in a rhesus maca-
que model of HIV transmission (Veazey et al., 2005). Taken
together, these findings support the further development of
C34 as a candidate microbicide.
In our previous studies, we tested candidate microbicides
only in the ‘‘pre/during’’ condition because our main goal
was to test drugs that downmodulated or blocked cell-surface
HIV receptors (e.g., CD4) and HIV co-receptors (e.g., CCR5)
(Kawamura et al., 2000, 2003, 2004). In this study, we
expanded our test culture conditions to include incubation
with drugs for 3 days following the 2-hour HIV exposure
period and incubation with drugs before, during, and after the
2-hour HIV exposure period. Taken together, our results using
drugs with different modes of action and in different culture
conditions suggest the following: (1) completely blocking
initial entry of HIV on the day of infection results in no
detectable HIV-infected LCs 3 days later, as occurs in the
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Figure 3. C34, PSC-RANTES, and AZT completely block HIV gag expression in LCs exposed to HIV. The number of HIV gag copies in LCs as determined
by quantitative real-time PCR is shown for three independent experiments using C34 (1 mM), PSC-RANTES (100 nM), or AZT (100 mM). (a) For C34 and AZT,
drugs were continuously present (‘‘all’’ conditions), whereas for PSC-RANTES, drug was present only before and during exposure to HIV (‘‘pre/during’’
condition). (b) Summary of the percent inhibition for each drug when compared to DNA isolated form LCs exposed to no drug.
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PSC-RANTES ‘‘pre/during’’ condition; (2) partial blocking by
C34 in the ‘‘pre/during’’ and the ‘‘post’’ conditions suggests
that a subset of virions that bind to CD4/CCR5 during the
2-hour infection period is blocked from fusing with cell
membranes, but that another subset is subsequently free to
fuse with cells and infect them after drug is washed out of the
system; (3) partial blocking by PSC-RANTES in the ‘‘post’’
condition suggests that roughly half of all HIV-infected LCs
detected on day 3 are infected during the 2-hour infection
period and that roughly half are infected during the 3-day
culture period; and (4) although not able to prevent virus
binding and viral entry, AZT, if continually present in LC
cultures, blocks active HIV replication in these cells.
It is now clear from numerous in vitro studies that there are
at least two pathways by which HIV interacts with dendritic
cell: (1) CD4- and CCR5-mediated infection by virus and
(2) cell-surface capture of virus by dendritic cell-SIGN and
other C-type lectins (Geijtenbeek et al., 2000; Turville et al.,
2001, 2002). Langerin is a C-type lectin specific to LC that
has been shown to bind HIV gp120 and mediate capture
when LCs are in cell suspension (Turville et al., 2002). It is
still unclear, however, whether dendritic cell in situ,
especially LCs embedded within epithelial cell layers, can
capture HIV via C-type lectins. Genetic studies have shown
that individuals with homozygous deletions in the open
reading frame of CCR5 are largely protected from initial HIV
infection despite numerous exposures (Dean et al., 1996;
Huang et al., 1996; Liu et al., 1996; Samson et al., 1996).
These observations suggest the importance of CCR5, and not
C-type lectins, as a critical cofactor involved in sexual
transmission of HIV. Using our skin tissue explant model, we
have found no evidence that C-type lectins expressed by LCs
within epithelium are involved in transmission of virus from
LCs to CD4þ T cells, both in previously published work
(Kawamura et al., 2003, 2004) and in this study (Figure 4 and
Table 1). Instead, our findings suggest that LC-mediated
transmission of virus to T cells ex vivo requires LC infection in
a CD4- and CCR5-dependent manner.
Blocking HIV infection of LCs at mucosal surfaces through
topical application of a microbicide appears to be valid
approach. In a proof of concept study, PSC-RANTES, when
applied intravaginally 15 minutes before intravaginal simian
immunodeficiency virus exposure, completely blocked
infection of rhesus macaques (Lederman et al., 2004).
Targeting of other early steps in the HIV life cycle, as
emphasized here, may also prove effective (Veazey et al.,
2005). Lastly, combination approaches using drugs with
different modes of action may provide protection in a
clinically meaningful manner, either through synergistic or
additive effects, or simply by reducing the amounts and costs
of drugs needed to provide complete protection.
MATERIALS AND METHODS
Healthy skin and blood donors
In accordance with the Declaration of Helsinki Principles, the
Institutional Review Board of the National Cancer Institute approved
all aspects of this study, and informed consent was obtained from
all healthy individuals volunteering for the suction blister
No drug C34 (all)
2.35%
0.16% 0.07%
0.06%
PSC-RANTES
(pre/during)
AZT (all)
HIV p24
CD
3
Figure 4. C34, PSC-RANTES, and AZT all block LC-mediated HIV infection
of co-cultured CD4þ T cells. ‘‘Crawl-out’’ LCs (1104) were collected 3
days after HIV exposure, washed three times, co-cultured with 1 106
allogeneic CD4þ T cells for 7 days, stained with anti-HIV p24 and anti-CD3
mAbs, and examined by flow cytometry. For C34 (1 mM) and AZT (100 mM),
drugs were continuously present (‘‘all’’ conditions), whereas for PSC-RANTES
(100 nM), drug was present only before and during exposure to HIV
(‘‘pre/during’’ condition). Representative dot plots from one of three
separate experiments are shown.
Table 1. LC-mediated HIV infection of co-cultured CD4+ T cells
Treatment of LC
HIV p24+ T cells by FACS
(%): day 7
Supernatant HIV p24
(ng/ml): day 5
Supernatant HIV p24
(ng/ml): day 7
No drug 1.2971.13 3.6271.27 16.2073.56
PSC-RANTES (pre/during) 0* 0.1570.31* 0.1970.38*
C34 (all) 0* 0.2370.33* 0.1270.23*
AZT (all) 0* 0.2970.58* 0.2270.43*
AZT, zidovudine; LC, Langerhans cell; RANTES, regulated on activation normal T-cell expressed and secreted.
*Po0.05 (compared to no drug).
The experiments were performed using skin explants from four different donors.
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procedure. Volunteers reported no histories of chronic disease
(including no histories of HIV risk factors) and no use of medications
on a regular basis.
Reagents
Phycoerythrin-conjugated mouse anti-human HLA-DR mAb (clone:
G46-6) and phycoerythrin-conjugated mouse anti-human CD3 mAb
(clone: UCHT1) were purchased from Pharmingen (San Diego, CA).
FITC-conjugated rat anti-p24 mAb was purchased from
Beckman-Coulter (Fullerton, CA). PSC-RANTES and C34 were
synthesized and purified as described previously (Chan et al.,
1997; Hartley et al., 2004). AZT was purchased from Sigma
Chemical Co. (St Louis, MO). Purified, pelleted, and titered HIVBaL
(stock at 107.67 TCID50/ml) was purchased from Advanced Bio-
technologies Inc. (Columbia, MD).
Inhibition of HIV infection in LCs ex vivo
Epithelial tissue explants were prepared from suction blister roofs of
healthy volunteers and LCs within these explants were infected as
described previously (Kawamura et al., 2000, 2003, 2004; Sugaya
et al., 2004). Briefly, 100 ml droplets containing HIVBaL at a 1:50
dilution were placed on the inside surface of sterile plastic culture
dish covers and explants were draped over droplets and incubated
together at 371C for 2 hours. For some experiments, 50ml droplets
containing AZT (200mM), PSC-RANTES (200 nM), or C34 (0.2 nM to
2mM) were placed on the inside surface of sterile plastic culture dish
covers. Explants were draped over droplets for 20 minutes
at 371C; 50 ml of HIVBaL at 1:50 final dilution was then added to
reagents under the explants and incubated for 2 additional
hours at 371C. Explants were washed three times with sterile
phosphate-buffered saline, and then floated in six-well plates
containing 4 ml of complete medium. For some experiments, culture
medium containing AZT (100 mM), PSC-RANTES (100 nM), or C34
(0.1 nM to 1 mM) was used.
Assessment of HIV transmission to CD4þ T cells
Allogeneic peripheral blood mononuclear cells were collected from
venous blood and were enriched for CD4þ T cells by negative
selection using a commercially prepared mAb mixture/complement
reagent (Lympho-Kwik; One Lambda, Los Angeles, CA; 490%
pure as assessed by flow cytometry). LCs (1 104) that crawled
out from epidermal sheets which had been treated with C34 (pre/
during/post HIV exposure), PSC-RANTES (pre/during HIV exposure),
or AZT (pre/during/post HIV exposure) were thoroughly washed
to minimize transfer of residual non-cell-associated virus or drugs
and then co-cultured with 1 106 allogeneic T cells in 24-well
plates for 7 days.
Assessment of LC and LC–T-cell infection by HIV
HIV infections of LC and LC–T-cell populations were assessed by
flow cytometry for intracellular HIV p24 protein and by ELISA for
HIV p24 protein levels in co-culture supernatants (Kawamura et al.,
2000, 2003, 2004). LC that had emigrated from tissue into media 3
days following HIV exposure of explants or LC–T-cell populations
co-cultured for 7 days were collected, passed through a 70-mM mesh,
washed three times in 2% human AB serum/phosphate-buffered
saline (staining buffer), pre-incubated in staining buffer for 10 min-
utes at room temperature to block nonspecific staining, and then
incubated with phycoerythrin-conjugated mouse anti-human HLA-
DR mAb or phycoerythrin-conjugated mouse anti-human CD3 mAb
for 30 minutes at 41C. Cells were then washed three times in staining
buffer, incubated with Dead Red (Molecular Probes, Eugene, OR) for
20 minutes at room temperature to label dead cells, washed
three times in staining buffer, and fixed and permeabilized with
cytofix/cytoperm reagents (Pharmingen) for 20 minutes at 41C. Cells
were then washed three times in PermWash (Pharmingen),
incubated with 10 mg/ml FITC-conjugated rat anti-p24 mAb
diluted in Perm/Wash for 30 minutes at 41C and examined by flow
cytometry using a FACScans (Becton Dickinson, Mountain
View, CA) equipped with LysisTM II software (Becton Dickinson).
Dead cells, that is, Dead Red-positive cells, were excluded from
all analyses. The percentages of HIV-infected LCs or T cells reported
here were always calculated by first subtracting any back-
ground values obtained when cells that had not been exposed to
HIV were stained.
For detection of secreted HIV p24 protein, supernatants were
harvested on days 5 and 7 from co-cultures of emigrated LCs and
CD4þ T cells, inactivated with 2% (v/v) Triton X-100 (Sigma) in
phosphate-buffered saline, and frozen at 201C. After collecting
supernatants, samples were thawed and examined for HIV p24
protein content by ELISA (Beckman Coulter, Miami, FL).
Quantitative real-time PCR for HIV gag DNA
The numbers of LC that had emigrated from tissue into media for 3
days were counted and DNA were purified using DNeasy Tissue kit
(Qiagen Inc., Valencia, CA). The total volume of DNA extracted
from LCs with the kit was 200ml. Quantitative real-time PCR was
then performed in a total volume of 50 ml, including 25 ml of SYBR
Green PCR Master Mix (Applied Biosystems, Foster City, CA), 1 ml of
each primer (final 500 nM), and 20 ml of DNA. Thermal amplification
was performed using the following linked profile: 10 minutes at
951C, 40 cycles of denaturation (951C for 15 seconds), and
annealing/extension (601C for 1 minutes) in a 7700 sequence
detection system (Applied Biosystems). Primer sequences used to
detect HIV gag DNA were SK38 and SK39 from GeneAmplimers
HIV Control reagents (Applied Biosystems). Positive control DNA of
the HIV genome was used for the standards and HIV gag copies per
105 cells were calculated.
Statistical analysis
Statistical analyses were performed using the Kruskal–Wallis test.
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